I

Integra LifeSciences

Regenerative medicine, surgical devices provider

End User Support Coordinator - Infrastructure and Operations

Full-TimeUpdated on 10/15/2026
No salary listed
Junior, Mid
Bachelor's, Associate's
Haifa, Israel
In Person
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • An associate degree in an Information Technology discipline, or an equivalent combination of experience and education.
  • A bachelor's degree in Computer Science or Information Technology, or an equivalent combination of experience and education.
  • One to three years of experience in a similar role; experience in a multinational or multi-site environment is ideal.
  • Service desk experience at Levels 1 and 2 is particularly valued.
  • Demonstrated knowledge of Windows Active Directory, Microsoft Office Suite, Microsoft Office 365, TCP/IP, and Windows desktop and laptop systems.
  • Understanding of the importance of documenting processes, procedures, and applications in a highly regulated medical devices environment.
  • Ability to manage multiple projects, activities, and tasks simultaneously.
  • Ability to work independently without close supervision.
  • Fluency in spoken and written English is essential.
  • Proactive approach to anticipating and preventing issues; attention to detail; ability to work as a team, escalate appropriately, share knowledge, and deliver on commitments.
  • Troubleshooting and problem-solving skills.
  • Documentation skills.
Responsibilities
  • Monitor the help desk ticketing system and provide timely, professional PC and peripheral support by phone, desk-side, or remote connection, including hardware and software installation and troubleshooting and occasional end-user education.
  • Accept and resolve assigned help desk tickets in a timely manner.
  • Provide initial basic instruction for PC, phone, mobile, and application access to new hires.
  • Provide after-hours support to end users and I&O staff as needed when on call.
  • Manage multifunctional and standalone printing devices, including paper and label printers.
  • Support MFG, R&D, and laboratory systems such as HMI, SCADA, and IO.
  • Support remote sites under the responsibilities of the Regional Manager, I&O.
  • Support validation activities related to the MFG process.
  • Support multifactor authentication.
  • Administer and support Windows Intune mobile device management.
  • Manage and support PC and iOS endpoint devices using SCCM, SCEP, and Windows Intune applications.
  • Administer and support Teams Voice.
  • Participate in group projects and other necessary tasks for the function.
  • Apply the standard corporate workstation image and deploy equipment to new employees; re-image existing employee PCs as needed without loss of data.
  • Recommend, deploy, and maintain hardware solutions, including end-user computing, mobile devices, servers, network equipment, and related devices.
  • Follow documented procedures, Integra SOPs, and controls, including permission reviews, backups, test restores, and patching; maintain required compliance evidence and provide it during SOX testing.
  • Create, maintain, and delete Windows Active Directory objects in accordance with company standards.
  • Assist the supervisor in completing tasks as requested.
  • Manage the data center's environmental controls, power, and cabling.
Desired Qualifications
  • Experience in a multinational or multi-site environment is ideal.
  • Service desk experience at Levels 1 and 2 is particularly valued.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical Insurance

Dental Insurance

Vision Insurance

Short-Term Disability

Long-Term Disability

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

4%

2 year growth

4%
Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.

Yahoo Finance
May 17th, 2026
Integra LifeSciences targets $200M operating cash flow as SurgiMend relaunch nears Q4

Integra LifeSciences reported first-quarter revenue and earnings per share above guidance, citing progress in its operational transformation efforts. Chief Financial Officer Lea Knight said internal indicators show fewer supply disruptions, better yields and improved cash flow. The company is maintaining its focus on neurosurgery, tissue reconstruction and ENT markets following a leadership change that saw Stuart return as chairman and CEO. Integra is preparing to relaunch SurgiMend in the fourth quarter after operationalising its Braintree manufacturing facility in June and rebuilding inventory in the third quarter. Management expects $25 million to $30 million in cost savings and is targeting approximately $200 million in operating cash flow and $140 million in free cash flow this year. The company also reported reduced tariff pressure, with full-year impacts now expected at $0.10 per share versus a prior estimate of $0.32.